LEUVAS THERAPEUTICS, Inc., a recently established biopharmaceutical company based in the California Bay Area and in Verona, Italy, is developing therapeutics that block leukocyte-vascular interactions (LVI) addressing clear unmet medical needs in large markets with potential for both first-in-class and best-in-class therapeutics addressing:
We are leveraging our recent discoveries that dysfunctional endothelium, inflammatory vascular changes, and leukocyte-vascular interactions (LVI) underlie disease pathogenesis in epilepsy, Alzheimer’s Disease and other common neurodegenerative diseases.
Contact us: firstname.lastname@example.org
Key Discoveries and Publications:
Neutrophils play a role in neurodegenerative disease; short-term blockade of leukocyte-vascular interactions at early and mid-stage of disease prevents cognitive decline in multiple models of Alzheimer's disease
PTPRG plays a previously unappreciated role in integrin activation and influences leukocyte migration; activation of PTPRG is a druggable target to modulate tyrosine phosphorylation.
TIM-1 is a major P-selectin ligand controlling T cell adhesion in inflamed vessels; TIM-1-mediated adhesion controls autoimmune and inflammatory disease development
Therapeutic blockade of leukocyte-vascular interactions blocks seizures and prevents epileptogenesis